NTLA
Price
$24.75
Change
-$0.16 (-0.64%)
Updated
Oct 17 closing price
Capitalization
2.66B
18 days until earnings call
Intraday Buy/Sell Signals
NTRB
Price
$7.48
Change
-$0.22 (-2.86%)
Updated
Oct 17 closing price
Capitalization
89.88M
44 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

NTLA vs NTRB

Header iconNTLA vs NTRB Comparison
Open Charts NTLA vs NTRBBanner chart's image
Intellia Therapeutics
Price$24.75
Change-$0.16 (-0.64%)
Volume$3.84M
Capitalization2.66B
Nutriband
Price$7.48
Change-$0.22 (-2.86%)
Volume$15.91K
Capitalization89.88M
NTLA vs NTRB Comparison Chart in %
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. NTRB commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and NTRB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (NTLA: $24.75 vs. NTRB: $7.48)
Brand notoriety: NTLA and NTRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 64% vs. NTRB: 50%
Market capitalization -- NTLA: $2.66B vs. NTRB: $89.88M
NTLA [@Biotechnology] is valued at $2.66B. NTRB’s [@Biotechnology] market capitalization is $89.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 0 FA rating(s) are green whileNTRB’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 0 green, 5 red.
  • NTRB’s FA Score: 0 green, 5 red.
According to our system of comparison, NTLA is a better buy in the long-term than NTRB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 5 TA indicator(s) are bullish while NTRB’s TA Score has 5 bullish TA indicator(s).

  • NTLA’s TA Score: 5 bullish, 4 bearish.
  • NTRB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than NTRB.

Price Growth

NTLA (@Biotechnology) experienced а +0.94% price change this week, while NTRB (@Biotechnology) price change was -0.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

NTLA is expected to report earnings on Nov 06, 2025.

NTRB is expected to report earnings on Dec 01, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($2.66B) has a higher market cap than NTRB($89.9M). NTLA YTD gains are higher at: 112.264 vs. NTRB (58.811). NTRB has higher annual earnings (EBITDA): -9.99M vs. NTLA (-501.87M). NTLA has more cash in the bank: 460M vs. NTRB (7M). NTRB has less debt than NTLA: NTRB (270K) vs NTLA (103M). NTLA has higher revenues than NTRB: NTLA (52.9M) vs NTRB (2.58M).
NTLANTRBNTLA / NTRB
Capitalization2.66B89.9M2,956%
EBITDA-501.87M-9.99M5,025%
Gain YTD112.26458.811191%
P/E RatioN/AN/A-
Revenue52.9M2.58M2,052%
Total Cash460M7M6,576%
Total Debt103M270K38,148%
FUNDAMENTALS RATINGS
NTLA vs NTRB: Fundamental Ratings
NTLA
NTRB
OUTLOOK RATING
1..100
7619
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
9798
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3546
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (37) in the Biotechnology industry is in the same range as NTRB (53) in the null industry. This means that NTLA’s stock grew similarly to NTRB’s over the last 12 months.

NTLA's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as NTRB (98) in the null industry. This means that NTLA’s stock grew similarly to NTRB’s over the last 12 months.

NTLA's SMR Rating (98) in the Biotechnology industry is in the same range as NTRB (100) in the null industry. This means that NTLA’s stock grew similarly to NTRB’s over the last 12 months.

NTLA's Price Growth Rating (35) in the Biotechnology industry is in the same range as NTRB (46) in the null industry. This means that NTLA’s stock grew similarly to NTRB’s over the last 12 months.

NTLA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NTRB (100) in the null industry. This means that NTLA’s stock grew similarly to NTRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLANTRB
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
71%
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 13 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NDVRX15.940.06
+0.38%
MFS New Discovery Value R1
VSGEX7.630.02
+0.26%
Virtus SGA International Growth C
RMOYX26.40-0.03
-0.11%
Victory RS Mid Cap Growth Y
WFDRX33.43-0.11
-0.33%
Allspring SMID Cap Growth Fund - Cl R6
SCIRX149.27-0.72
-0.48%
Columbia Seligman Tech & Info R

NTRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTRB has been loosely correlated with ABSI. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRB jumps, then ABSI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTRB
1D Price
Change %
NTRB100%
-2.86%
ABSI - NTRB
33%
Loosely correlated
-6.98%
VRAX - NTRB
31%
Poorly correlated
-1.06%
NRIX - NTRB
29%
Poorly correlated
-1.89%
DNLI - NTRB
29%
Poorly correlated
-0.36%
NTLA - NTRB
28%
Poorly correlated
-0.64%
More